Riskpilot← Back to searchSign inGet full accessPronotice AB
ABActiveOrg 5592782386Nybrogatan 66Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20200 employees
Revenue 2024
SEK 10,4M
+103% vs 2023
EBITDA margin
11.8%
+633% vs 2023
Equity ratio
0.9%
Financial strength
Net profit 2024
SEK -133K
-206% vs 2023
| Revenue | SEK 10,4M | +103% |
| EBITDA | SEK 1,2M | +633% |
| Net profit | SEK -133K | -206% |
| Total assets | SEK 3,3M | -5% |
| Equity | SEK 29K | -82% |
| Employees | 0 | — |
Legal name
Pronotice AB
Org number
5592782386
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
22 oktober 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget skall bedriva utveckling, import, export, försäljning och marknadsföring av medicintekniska produkter, samt därmed förenlig verksamhet.
Address
Nybrogatan 66
Email
contact@pronoticegroup.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 247 | 18 760 | 50 916 | 5 120 | 10 392 |
| Staff expenses | — | — | — | — | −3 156 |
| EBITDA | 229 | 3 186 | 8 357 | −229 | 1 221 |
| Depreciation & amort. | −0 | −0 | −0 | −20 | −39 |
| EBIT | 229 | 3 186 | 8 357 | −249 | 1 182 |
| Net financials | — | — | 84 | 319 | −49 |
| Profit before tax | 229 | 3 186 | 8 441 | 1 569 | 1 133 |
| Tax | −49 | −656 | −1 739 | −1 444 | −1 266 |
| Net profit | 180 | 2 530 | 6 702 | 125 | −133 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 213 | 9 751 | 10 226 | 3 408 | 3 250 |
| Equity | 205 | 2 734 | 7 437 | 162 | 29 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 4 008 | 7 016 | 2 789 | 3 246 | 3 221 |
| Total debt | 4 008 | 7 016 | 2 789 | 3 246 | 3 221 |
EBITDA margin
11.8%
This company
15.8%
Market median
-25% vs market
20202024
Equity ratio
0.9%
This company
38.2%
Market median
-98% vs market
20202024
Return on equity
-453.6%
This company
18.4%
Market median
-2565% vs market
20202024
Net profit margin
-1.3%
This company
8.1%
Market median
-116% vs market
20202024
Asset turnover
3.20×
This company
1.12×
Market median
+186% vs market
20202024
Debt / equity
110.01×
This company
0.62×
Market median
-17644% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-10-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AR Chief Auditor | Chief Auditor | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2024 | |
| Board of Directors | 2021 | |
| Former (2) | ||
| Board of Directors | 2021 – 2021 | |
| Deputy Board Member | 2021 – 2024 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vossat Group AB
Pronotice AB Board members of Pronotice AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anna Rozhdestvenskaya | Chief Auditor | 0 companies |
| Jan Torkel Furuvald | Board of Directors | 0 companies |
| Ada Caroline Furuvald | Deputy Board Member | 0 companies |
| Gian Carlo Maria Perez | Deputy Board Member | 0 companies |
| Madeleine Furuvald | Board of Directors | 0 companies |